Scholar Rock Holding Corp
About Scholar Rock Holding Corp
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $0
- Net income
- -$377.9M
- Total assets
- $404.3M
- Market cap
- $5.3B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $384.6M
- Operating income
- -$384.6M
- Net income
- -$377.9M
- EPS (basic)
- $-3.29
- EPS (diluted)
- $-3.29
Balance sheet
- Total assets
- $404.3M
- Current assets
- $385.1M
- Total liabilities
- $158.8M
- Current liabilities
- $55.4M
- Shareholders’ equity
- $245.5M
Cash flow
- Operating cash flow
- -$300.0M
- Investing cash flow
- $218.7M
- Financing cash flow
- $228.4M
- Net cash flow
- $147.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $5.3B
- EPS (diluted)
- $-3.29
- Shares outstanding
- 121.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 24, 2018
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $377.9M in FY2025.
- Trading 15% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Scholar Rock Holding Corp.
Write a review
News about Scholar Rock Holding Corp
News & sentiment via Polygon.io
